<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722042</url>
  </required_header>
  <id_info>
    <org_study_id>20-3022</org_study_id>
    <secondary_id>R21DC018389</secondary_id>
    <nct_id>NCT04722042</nct_id>
  </id_info>
  <brief_title>Place-based Mapping in EAS Listeners</brief_title>
  <official_title>Place-based Mapping in Electric-acoustic Stimulation Listeners</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: Investigate monaural and binaural hearing in electric-acoustic stimulation (EAS)&#xD;
      users with place-based versus default maps.&#xD;
&#xD;
      Participants: Cochlear implant recipients and normal-hearing listeners Procedures (methods):&#xD;
      This is a prospective, longitudinal investigation of the monaural and binaural outcomes (such&#xD;
      as speech perception, spatial hearing, and/or subjective benefit) of cochlear implant&#xD;
      recipients listening with different programs. The programs will incorporate different patient&#xD;
      and device variables to determine the effect on cochlear implant recipient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized to one of two groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monaural perception over time</measure>
    <time_frame>Up to 12 months post-activation</time_frame>
    <description>Monaural perception (e.g., word recognition in quiet) will be assessed at defined intervals (e.g., activation, and 1, 3, 6, and 12 months post-activation). Performance (e.g., percent correct) will be compared within-subject and between group over the study intervals.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binaural hearing abilities over time</measure>
    <time_frame>Up to 12 months post-activation</time_frame>
    <description>Binaural hearing abilities (e.g., spatial release from masking) will be assessed at defined intervals (e.g., 1, 3, 6, and 12 months post-activation). Performance (e.g., percent correct) will be compared within-subject and between group over the study intervals.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived abilities over time</measure>
    <time_frame>Up to 12 months post-activation</time_frame>
    <description>Perceived abilities will be assessed with questionnaires (e.g., Speech, Spatial, and Qualities of hearing scale; SSQ) at defined intervals (e.g., activation, and 1, 3, 6, and 12 months post-activation). A subject indicates his/her perceived abilities for each question on the SSQ using a Likert scale, with a range of 0-10 (with 10 indicating better perceived abilities). Responses will be compared between group over the study intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cochlear Implant</condition>
  <arm_group>
    <arm_group_label>Default</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The default frequency filters assigned by the clinical software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Place-based</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Frequency filters adjusted to align with the cochlear place frequency</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>place-based mapping</intervention_name>
    <description>Adjusting the electric frequency filters to align with the cochlear place frequency</description>
    <arm_group_label>Place-based</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>default mapping</intervention_name>
    <description>Default frequency filter assignments</description>
    <arm_group_label>Default</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Cochlear implant participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years of age at implantation, identify English as native language, Medical&#xD;
             Electronics (MED-EL) array recipient, and a postoperative unaided detection threshold&#xD;
             of less than or equal to 65 decibel (dB) hearing level (HL) at 125 Hz&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Report or present with a cognitive delay or impairment&#xD;
&#xD;
        Normal-hearing controls&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  18-80 years of age at time of testing, unaided detection thresholds of 35 dB HL or&#xD;
             better from 500-4000 Hz, identify English as native language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Report or present with a cognitive delay or impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret T Dillon, AuD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin D Brown, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Dillon, AuD</last_name>
    <phone>919-966-5251</phone>
    <email>mdillon@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC ENT at Carolina Crossing</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Dillon, AuD</last_name>
    </contact>
    <investigator>
      <last_name>Margaret Dillon, AuD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin Brown, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Buss, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meredith Rooth, AuD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Canfarotta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.</ipd_description>
    <ipd_time_frame>beginning 9 to 36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Investigator who proposes to use the data has approval from an IRB, IEC, or REB, as applicable, and an executed data use/sharing agreement with UNC.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

